var data={"title":"Ganciclovir and valganciclovir: An overview","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Ganciclovir and valganciclovir: An overview</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Kimon C Zachary, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 08, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> was the first antiviral agent approved for the treatment of cytomegalovirus (CMV) infection. It is widely used for the treatment of CMV infections among patients with impaired cell-mediated immunity, particularly persons with poorly controlled and advanced <span class=\"nowrap\">HIV/AIDS,</span> and recipients of solid organ and bone marrow transplantation, who are at high risk for invasive CMV disease. <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">Valganciclovir</a>, an oral prodrug that is rapidly converted to ganciclovir, also plays a major role in the treatment and prevention of CMV infections in immunocompromised hosts. </p><p>An overview of the basic pharmacology, pharmacokinetics, and toxicities of <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> and <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> will be discussed here. Treatment of specific clinical syndromes can be found in the appropriate topics. (See <a href=\"topic.htm?path=treatment-of-aids-related-cytomegalovirus-retinitis\" class=\"medical medical_review\">&quot;Treatment of AIDS-related cytomegalovirus retinitis&quot;</a> and <a href=\"topic.htm?path=aids-related-cytomegalovirus-gastrointestinal-disease\" class=\"medical medical_review\">&quot;AIDS-related cytomegalovirus gastrointestinal disease&quot;</a> and <a href=\"topic.htm?path=cytomegalovirus-infection-as-a-cause-of-pulmonary-disease-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-management-of-cytomegalovirus-disease-in-kidney-transplant-recipients\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant recipients&quot;</a> and <a href=\"topic.htm?path=prevention-of-cytomegalovirus-infection-in-lung-transplant-recipients\" class=\"medical medical_review\">&quot;Prevention of cytomegalovirus infection in lung transplant recipients&quot;</a> and <a href=\"topic.htm?path=pulmonary-complications-after-allogeneic-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Pulmonary complications after allogeneic hematopoietic cell transplantation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MECHANISM OF ACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> (9<strong>-</strong>[(1,3,-dihydroxy-2-propoxy)methyl] guanine, or DHPG) is an acyclic analog of the nucleoside guanosine. The drug is converted intracellularly to ganciclovir 5'-monophosphate by a viral kinase, which is encoded by the cytomegalovirus (CMV) gene UL97 during infection. Subsequently, cellular kinases catalyze the formation of ganciclovir diphosphate and ganciclovir triphosphate, which is present in 10-fold greater concentrations in CMV or herpes simplex virus (HSV)-infected cells than uninfected cells. </p><p><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> triphosphate is a competitive inhibitor of deoxyguanosine triphosphate incorporation into DNA and preferentially inhibits viral DNA polymerases more than cellular DNA polymerases. In addition, ganciclovir triphosphate serves as a poor substrate for chain elongation, thereby disrupting viral DNA synthesis by a second route [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/1-3\" class=\"abstract_t\">1-3</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">SPECTRUM OF ACTIVITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> and <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> are used primarily in treating cytomegalovirus (CMV) infections. In vitro synergy with <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> has been observed against CMV [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=foscarnet-an-overview\" class=\"medical medical_review\">&quot;Foscarnet: An overview&quot;</a>.)</p><p><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> also inhibits the replication of other herpesviruses in vitro, including herpes simplex virus types 1 and 2 (HSV-1, HSV-2), Epstein-Barr virus (EBV), varicella-zoster virus (VZV), human herpes virus 6 (HHV-6), and herpes simian B virus at clinically achievable concentrations [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Ganciclovir is considered the drug of choice for symptomatic herpes simian B virus disease, including central nervous system infections [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/4\" class=\"abstract_t\">4</a>]. However, other antiviral agents, such as <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a>, or <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> are usually preferred over ganciclovir for treatment of HSV infections [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/5\" class=\"abstract_t\">5</a>]. There are scant data on the use of ganciclovir or <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> for the treatment of severe EBV or HHV-6 infections in the immunocompromised host [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/6,7\" class=\"abstract_t\">6,7</a>]. (See <a href=\"topic.htm?path=human-herpesvirus-6-infection-in-hematopoietic-cell-transplant-recipients#H709290675\" class=\"medical medical_review\">&quot;Human herpesvirus 6 infection in hematopoietic cell transplant recipients&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-post-transplant-lymphoproliferative-disorders#H16\" class=\"medical medical_review\">&quot;Treatment and prevention of post-transplant lymphoproliferative disorders&quot;, section on 'Treatment'</a>.) </p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">MECHANISMS OF RESISTANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> resistance can occur in patients receiving prolonged therapy with either intravenous (IV) ganciclovir or oral <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a>. One study of 76 AIDS patients with cytomegalovirus (CMV) retinitis treated initially with ganciclovir reported resistance in 11 percent of patients at six months of treatment and 28 percent at nine months [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/8\" class=\"abstract_t\">8</a>].</p><p>Mutations in the UL97-encoded CMV phosphotransferase have been associated with resistance [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/9\" class=\"abstract_t\">9</a>], as have alterations in UL54-encoded viral DNA polymerase [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/10\" class=\"abstract_t\">10</a>]. It has been postulated that UL97 mutations arise first and confer moderate resistance to <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> but not to other CMV antivirals, such as <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> or <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a>. With continued therapy, DNA polymerase mutations may subsequently appear, leading to high-level resistance to ganciclovir with cross-resistance to cidofovir and, sometimes, resistance to foscarnet [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/11-13\" class=\"abstract_t\">11-13</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">BASIC PHARMACOKINETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> is excreted, unmodified, in the urine with a plasma half-life of two to four hours; the intracellular half-life of ganciclovir triphosphate is considerably longer, about 16.5 hours. Clearance is directly correlated to glomerular filtration rate; therefore, dosage adjustment is required in patients with impaired renal function [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Ganciclovir is also available as an oral capsule, but this formulation has poor bioavailability and is no longer marketed in the United States. For both oral <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> and IV ganciclovir, hemodialysis decreases the serum concentration by about 50 percent [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/14-16\" class=\"abstract_t\">14-16</a>]. (See <a href=\"#H347682928\" class=\"local\">'Dose modification'</a> below.)</p><p><a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">Valganciclovir</a>, an L-valyl ester of <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a>, is well absorbed after oral administration and rapidly hydrolyzed to ganciclovir in the intestinal wall and liver [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/17,18\" class=\"abstract_t\">17,18</a>]. The absolute bioavailability of ganciclovir from valganciclovir tablets (taken with food) is approximately 60 percent [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/18\" class=\"abstract_t\">18</a>]. Systemic exposure of a 900 mg dose of valganciclovir in adults is similar to that attained by a single dose of 5 <span class=\"nowrap\">mg/kg</span> of intravenous ganciclovir [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/17,19-21\" class=\"abstract_t\">17,19-21</a>]. Given this favorable oral bioavailability, oral valganciclovir essentially replaced oral ganciclovir capsules.</p><p class=\"headingAnchor\" id=\"H25347350\"><span class=\"h1\">ROUTES OF ADMINISTRATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> is given primarily as an intravenous formulation rather than orally because of its poor bioavailability (ie, 6 percent) that is only modestly increased by food [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/2,3\" class=\"abstract_t\">2,3</a>]. Oral ganciclovir is no longer available in the United States. Intravenous ganciclovir is usually used for induction treatment of severe cytomegalovirus (CMV) disease in HIV infected individuals, and transplant recipients. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-cytomegalovirus-infection-in-lung-transplant-recipients#H709584933\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients&quot;, section on 'Treatment of active disease'</a> and <a href=\"topic.htm?path=treatment-of-aids-related-cytomegalovirus-retinitis#H446525724\" class=\"medical medical_review\">&quot;Treatment of AIDS-related cytomegalovirus retinitis&quot;, section on 'Systemic therapy'</a> and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-management-of-cytomegalovirus-disease-in-kidney-transplant-recipients#H2533840316\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant recipients&quot;, section on 'Antiviral therapy'</a>.)</p><p><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> can also be given intraocularly for the treatment of CMV retinitis. Although a sustained-release ganciclovir intraocular implant was previously available for the treatment of CMV retinitis, it is no longer being produced and is therefore not a treatment option. Intraocular injections, in conjunction with systemic therapy, are currently recommended for the treatment of immediate sight threatening retinitis [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/22\" class=\"abstract_t\">22</a>]. (See <a href=\"topic.htm?path=treatment-of-aids-related-cytomegalovirus-retinitis#H446525662\" class=\"medical medical_review\">&quot;Treatment of AIDS-related cytomegalovirus retinitis&quot;, section on 'Intravitreal therapy'</a>.)</p><p>The development of oral <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> was a major advance in the treatment and prevention of CMV disease in both HIV and non-HIV infected patients. Valganciclovir provides excellent systemic concentrations of drug and has the advantage of avoiding the complications associated with chronic intravenous or intraocular therapies [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/17,23\" class=\"abstract_t\">17,23</a>]. (See <a href=\"topic.htm?path=prevention-of-infections-in-hematopoietic-cell-transplant-recipients#H1105849631\" class=\"medical medical_review\">&quot;Prevention of infections in hematopoietic cell transplant recipients&quot;, section on 'Antiviral prophylaxis or preemptive therapy'</a> and <a href=\"topic.htm?path=treatment-of-aids-related-cytomegalovirus-retinitis#H446525724\" class=\"medical medical_review\">&quot;Treatment of AIDS-related cytomegalovirus retinitis&quot;, section on 'Systemic therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H12196018\"><span class=\"h1\">DOSING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The usual dose of <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> for induction therapy is 5 <span class=\"nowrap\">mg/kg</span> every 12 hours, followed by 5 <span class=\"nowrap\">mg/kg</span> as a single daily infusion for maintenance therapy. The duration of induction therapy depends on the host and the severity of disease. Generally speaking, the duration of induction is 14 to 21 days in an HIV-infected host and 7 to 14 days in a transplant recipient. </p><p>In patients able to take and absorb oral medications, <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> is a reasonable alternative to intravenous (IV) <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> for both induction and maintenance therapy [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/24\" class=\"abstract_t\">24</a>]. The dosing of valganciclovir, in adult patients with normal renal function, is 900 mg twice daily during induction therapy followed by 900 mg once daily during maintenance therapy. (See <a href=\"topic.htm?path=treatment-of-aids-related-cytomegalovirus-retinitis#H446525724\" class=\"medical medical_review\">&quot;Treatment of AIDS-related cytomegalovirus retinitis&quot;, section on 'Systemic therapy'</a> and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-management-of-cytomegalovirus-disease-in-kidney-transplant-recipients#H2533840316\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant recipients&quot;, section on 'Antiviral therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H347682928\"><span class=\"h2\">Dose modification</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We administer <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> to patients with renal dysfunction; however, the dose must be modified. Empiric dose adjustments for valganciclovir can be based upon measured or estimated creatinine clearance (CrCl) [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/22,25\" class=\"abstract_t\">22,25</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&ge;60 <span class=\"nowrap\">mL/min:</span> Usual dose (ie, 900 mg every 12 hours for induction; 900 mg once daily for maintenance)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>40-59 <span class=\"nowrap\">mL/min:</span> 450 mg every 12 hours for induction; 450 mg once daily for maintenance</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>25-39 <span class=\"nowrap\">mL/min:</span> 450 mg once daily for induction; 450 mg every 48 hours for maintenance</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>10-24 <span class=\"nowrap\">mL/min:</span> 450 mg every 48 hours for induction; 450 mg twice per week for maintenance</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&lt;10 <span class=\"nowrap\">mL/min</span> but not on dialysis: Use IV <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> or consider 200 mg oral suspension three times per week for induction; 100 mg oral suspension three times per week for maintenance</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemodialysis: 200 mg oral suspension three times per week after dialysis for induction; 100 mg oral suspension three times per week after dialysis for maintenance</p><p/><p>Dose modification of IV ganciclovir in patients with renal dysfunction is reviewed separately. See <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> (systemic): Drug information, section Dosing: Renal Impairment. </p><p>The dosing of intraocular <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> for the treatment of immediate sight threatening CMV retinitis is discussed elsewhere. (See <a href=\"topic.htm?path=treatment-of-aids-related-cytomegalovirus-retinitis#H446525662\" class=\"medical medical_review\">&quot;Treatment of AIDS-related cytomegalovirus retinitis&quot;, section on 'Intravitreal therapy'</a>.) </p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">TOXICITY</span></p><p class=\"headingAnchor\" id=\"H4687077\"><span class=\"h2\">Bone marrow suppression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> and <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> are both associated with bone marrow suppression, particularly leukopenia [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/26\" class=\"abstract_t\">26</a>]. The frequency and severity of these hematologic abnormalities varies widely in different patient populations. </p><p>Many potential recipients of these drugs, particularly patients with hematologic malignancies or advanced <span class=\"nowrap\">HIV/AIDS,</span> also have other factors contributing to myelosuppression [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/27\" class=\"abstract_t\">27</a>]. In fact, disseminated cytomegalovirus (CMV) per se characteristically suppresses bone marrow production, but antiviral therapy usually results in improvement of hematologic parameters. However, <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> and <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> should be used with caution in patients with pre-existing cytopenias; neither drug should be used when the absolute neutrophil count is under 500 <span class=\"nowrap\">cells/microL</span> or when the platelet count is under <span class=\"nowrap\">25,000/microL</span> [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/28\" class=\"abstract_t\">28</a>].</p><p>Hematopoietic growth factors (eg, granulocyte-colony stimulating factor, G-CSF or granulocyte macrophage colony-stimulating factor, GM-CSF) are widely used to counter the effects of myelosuppressive drugs, such as chemotherapeutic agents, and can be given to manage neutropenia in patients receiving <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> or <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/3,29-34\" class=\"abstract_t\">3,29-34</a>]. Hematopoietic growth factors are particularly useful when ongoing anti-CMV treatment is necessary and the disadvantage of switching to <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> is judged to outweigh the risks of myelosuppression. These growth factors are well tolerated and have been shown to facilitate ganciclovir and valganciclovir dosing [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/35-37\" class=\"abstract_t\">35-37</a>]. Growth factors also reduce the risk of bacterial infections, which may be secondary to improved neutrophil chemotaxis and phagocytosis [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/33,38,39\" class=\"abstract_t\">33,38,39</a>]. </p><p class=\"headingAnchor\" id=\"H4687084\"><span class=\"h2\">Renal insufficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In some placebo-controlled trials, intravenous <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> has been associated with an increased frequency of elevated serum creatinine; concomitant administration of other medications with well-known nephrotoxicity, such as <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, has been a frequent confounder [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/28\" class=\"abstract_t\">28</a>]. The mechanism of nephrotoxicity is unknown, and the risk associated with ganciclovir per se appears to be low. Nevertheless, frequent monitoring of renal function is necessary, at least as much to ensure proper dosing as to look for nephrotoxicity.</p><p class=\"headingAnchor\" id=\"H4686872\"><span class=\"h1\">DRUG INTERACTIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are many potential drug interactions and overlapping toxicities between <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> and other agents, particularly cytoreductive chemotherapeutics and immunosuppressive drugs commonly administered to transplant patients [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/40\" class=\"abstract_t\">40</a>]. In such cases, increased frequency of laboratory monitoring is advisable and alternative treatment may be necessary. </p><p>Nephrotoxicity induced by other drugs (for example, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> and amphotericin B) reduces the clearance of <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> and thereby increases the risk of myelosuppression. <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">Trimethoprim-sulfamethoxazole</a>, especially at high doses such as those used to treat Pneumocystis pneumonia and nocardiosis, can be both myelosuppressive and nephrotoxic, and therefore co-administration of ganciclovir can be problematic. Co-administration of ganciclovir and <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> may increase the risk of seizures beyond that of imipenem alone [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H25347319\"><span class=\"h1\">PATIENT MONITORING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Given the risk of bone marrow suppression, patients receiving <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> or <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> should have a complete blood count (CBC) with a differential at least twice a week during induction therapy. </p><p>In addition, renal function testing such as serum blood urea nitrogen (BUN) and creatinine should be checked at least weekly during induction therapy, since a decline in renal function may require adjusting the dose of <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/41\" class=\"abstract_t\">41</a>]. The risk of direct nephrotoxicity is low, but patients receiving ganciclovir are often at increased risk for kidney injury related to comorbidities and nephrotoxic medications [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/40\" class=\"abstract_t\">40</a>]. More frequent monitoring should be considered in patients at particularly high risk for nephrotoxicity, such as those receiving <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, aminoglycosides, or amphotericin B (including liposomal preparations).</p><p>During maintenance therapy, the frequency of laboratory monitoring can be reduced and should be individualized. At a minimum, serum creatinine and a complete blood count with differential should be checked at least once a month. </p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">USE IN PREGNANCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> is classified as a pregnancy category C substance, there are no adequate studies of ganciclovir in pregnant women. Women of child-bearing age should be counseled to use effective contraception during treatment. Similarly, men should be advised to practice barrier contraception during and for at least 90 days following treatment [<a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/42\" class=\"abstract_t\">42</a>].</p><p class=\"headingAnchor\" id=\"H25346986\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a>, a nucleoside analog, disrupts viral DNA synthesis through selective incorporation of ganciclovir triphosphate, which terminates DNA chain elongation. (See <a href=\"#H2\" class=\"local\">'Mechanism of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> has been primarily used for treatment of cytomegalovirus (CMV) infections, although it does have in vitro activity against other herpesviruses, such as human herpes virus 6 (HHV-6). (See <a href=\"#H3\" class=\"local\">'Spectrum of activity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> resistance, which is associated with mutations in CMV phosphotransferase and DNA polymerase, is seen mainly among immunocompromised patients receiving prolonged therapy. (See <a href=\"#H2\" class=\"local\">'Mechanism of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> is excreted, unmodified, in the urine with a plasma half-life of two to four hours. Dosage adjustment is required in patients with impaired renal function. (See <a href=\"#H5\" class=\"local\">'Basic pharmacokinetics'</a> above and <a href=\"#H347682928\" class=\"local\">'Dose modification'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> is available intravenously and orally, although the bioavailability of oral ganciclovir is poor. Oral ganciclovir has been essentially replaced by oral <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a>, a well-absorbed prodrug that is rapidly converted to ganciclovir. Oral valganciclovir (900 mg) can achieve similar systemic exposure as a standard dose of intravenous ganciclovir (5 <span class=\"nowrap\">mg/kg)</span>. (See <a href=\"#H25347350\" class=\"local\">'Routes of administration'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intraocular injections of <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> plus systemic ganciclovir are indicated for the treatment of immediate sight threatening CMV retinitis. Ganciclovir implants are no longer produced. (See <a href=\"#H25347350\" class=\"local\">'Routes of administration'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> and <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> are associated with bone marrow suppression, particularly leukopenia, which can usually be managed with hematopoietic growth factors. (See <a href=\"#H6\" class=\"local\">'Toxicity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>During <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> or <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">valganciclovir</a> therapy, patients should be monitored for hematologic and renal toxicity. Prior to administration, drug-drug interactions should also be reviewed by the clinician. (See <a href=\"#H25347319\" class=\"local\">'Patient monitoring'</a> above and <a href=\"#H4686872\" class=\"local\">'Drug interactions'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/1\" class=\"nounderline abstract_t\">Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335:721.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/2\" class=\"nounderline abstract_t\">Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990; 39:597.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/3\" class=\"nounderline abstract_t\">Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994; 48:455.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/4\" class=\"nounderline abstract_t\">Cohen JI, Davenport DS, Stewart JA, et al. Recommendations for prevention of and therapy for exposure to B virus (cercopithecine herpesvirus 1). Clin Infect Dis 2002; 35:1191.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/5\" class=\"nounderline abstract_t\">Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol 2010; 49:151.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/6\" class=\"nounderline abstract_t\">Venturi C, Bueno J, Gavalda J, et al. Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report. Transplant Proc 2009; 41:1038.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/7\" class=\"nounderline abstract_t\">Seeley WW, Marty FM, Holmes TM, et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology 2007; 69:156.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/8\" class=\"nounderline abstract_t\">Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis 1998; 177:770.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/9\" class=\"nounderline abstract_t\">Chou S, Guentzel S, Michels KR, et al. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995; 172:239.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/10\" class=\"nounderline abstract_t\">Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992; 66:7146.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/11\" class=\"nounderline abstract_t\">Erice A, Gil-Roda C, P&eacute;rez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175:1087.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/12\" class=\"nounderline abstract_t\">Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. J Infect Dis 1997; 176:50.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/13\" class=\"nounderline abstract_t\">Smith IL, Cherrington JM, Jiles RE, et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176:69.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/14\" class=\"nounderline abstract_t\">Lake KD, Fletcher CV, Love KR, et al. Ganciclovir pharmacokinetics during renal impairment. Antimicrob Agents Chemother 1988; 32:1899.</a></li><li class=\"breakAll\">Valganciclovir.  US Food &amp; Drug Administration (FDA) approved product information.  Revised March, 2013.  US National Library of Medicine. http://www.dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on October 30, 2014).</li><li class=\"breakAll\">Ganciclovir sodium injection. US Food &amp; Drug Administration (FDA) approved product information.  Revised August, 2010.  US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on October 30, 2014).</li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/17\" class=\"nounderline abstract_t\">Cvetkovi&#263; RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005; 65:859.</a></li><li class=\"breakAll\">Genentech, Inc. Valcyte full prescribing information. http://www.gene.com/gene/products/information/valcyte/pdf/pi.pdf (Accessed on April 10, 2012).</li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/19\" class=\"nounderline abstract_t\">Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet 1999; 37:167.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/20\" class=\"nounderline abstract_t\">Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44:2811.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/21\" class=\"nounderline abstract_t\">Curran M, Noble S. Valganciclovir. Drugs 2001; 61:1145.</a></li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. (Accessed on July 08, 2014).</li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/23\" class=\"nounderline abstract_t\">Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/24\" class=\"nounderline abstract_t\">Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346:1119.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/25\" class=\"nounderline abstract_t\">Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e96.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/26\" class=\"nounderline abstract_t\">Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/27\" class=\"nounderline abstract_t\">Groopman JE. Antiretroviral therapy and immunomodulators in patients with AIDS. Am J Med 1991; 90:18S.</a></li><li class=\"breakAll\">Genentech, Inc., 2010. Cytovene-IV (ganciclovir sodium for injection). http://www.gene.com/gene/products/information/cytovene/pdf/pi.pdf (Accessed on July 23, 2012).</li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/29\" class=\"nounderline abstract_t\">Scadden DT, Bering HA, Levine JD, et al. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991; 9:802.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/30\" class=\"nounderline abstract_t\">Miles SA, Mitsuyasu RT, Moreno J, et al. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 1991; 77:2109.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/31\" class=\"nounderline abstract_t\">Davey RT Jr, Davey VJ, Metcalf JA, et al. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 1991; 164:43.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/32\" class=\"nounderline abstract_t\">Walsh C, Wernz JC, Levine A, et al. Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 1993; 6:265.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/33\" class=\"nounderline abstract_t\">Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998; 12:65.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/34\" class=\"nounderline abstract_t\">Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis 2000; 30:256.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/35\" class=\"nounderline abstract_t\">Hardy D, Spector S, Polsky B, et al. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team. Eur J Clin Microbiol Infect Dis 1994; 13 Suppl 2:S34.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/36\" class=\"nounderline abstract_t\">Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991; 9:929.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/37\" class=\"nounderline abstract_t\">Ross SD, DiGeorge A, Connelly JE, et al. Safety of GM-CSF in patients with AIDS: a review of the literature. Pharmacotherapy 1998; 18:1290.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/38\" class=\"nounderline abstract_t\">Grant SM, Heel RC. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelosuppression. Drugs 1992; 43:516.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/39\" class=\"nounderline abstract_t\">Pitrak DL. Filgrastim treatment of HIV-infected patients improves neutrophil function. AIDS 1999; 13 Suppl 2:S25.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/40\" class=\"nounderline abstract_t\">Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm 2010; 67:1417.</a></li><li><a href=\"https://www.uptodate.com/contents/ganciclovir-and-valganciclovir-an-overview/abstract/41\" class=\"nounderline abstract_t\">Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004; 38:1651.</a></li><li class=\"breakAll\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019661s030lbl.pdf (Accessed on July 19, 2012).</li></ol></div><div id=\"topicVersionRevision\">Topic 8342 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H25346986\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MECHANISM OF ACTION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">SPECTRUM OF ACTIVITY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">MECHANISMS OF RESISTANCE</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">BASIC PHARMACOKINETICS</a></li><li><a href=\"#H25347350\" id=\"outline-link-H25347350\">ROUTES OF ADMINISTRATION</a></li><li><a href=\"#H12196018\" id=\"outline-link-H12196018\">DOSING</a><ul><li><a href=\"#H347682928\" id=\"outline-link-H347682928\">Dose modification</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">TOXICITY</a><ul><li><a href=\"#H4687077\" id=\"outline-link-H4687077\">Bone marrow suppression</a></li><li><a href=\"#H4687084\" id=\"outline-link-H4687084\">Renal insufficiency</a></li></ul></li><li><a href=\"#H4686872\" id=\"outline-link-H4686872\">DRUG INTERACTIONS</a></li><li><a href=\"#H25347319\" id=\"outline-link-H25347319\">PATIENT MONITORING</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">USE IN PREGNANCY</a></li><li><a href=\"#H25346986\" id=\"outline-link-H25346986\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=aids-related-cytomegalovirus-gastrointestinal-disease\" class=\"medical medical_review\">AIDS-related cytomegalovirus gastrointestinal disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-management-of-cytomegalovirus-disease-in-kidney-transplant-recipients\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-cytomegalovirus-infection-in-lung-transplant-recipients\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cytomegalovirus-infection-as-a-cause-of-pulmonary-disease-in-hiv-infected-patients\" class=\"medical medical_review\">Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=foscarnet-an-overview\" class=\"medical medical_review\">Foscarnet: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=human-herpesvirus-6-infection-in-hematopoietic-cell-transplant-recipients\" class=\"medical medical_review\">Human herpesvirus 6 infection in hematopoietic cell transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-cytomegalovirus-infection-in-lung-transplant-recipients\" class=\"medical medical_review\">Prevention of cytomegalovirus infection in lung transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-infections-in-hematopoietic-cell-transplant-recipients\" class=\"medical medical_review\">Prevention of infections in hematopoietic cell transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-complications-after-allogeneic-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Pulmonary complications after allogeneic hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-post-transplant-lymphoproliferative-disorders\" class=\"medical medical_review\">Treatment and prevention of post-transplant lymphoproliferative disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-aids-related-cytomegalovirus-retinitis\" class=\"medical medical_review\">Treatment of AIDS-related cytomegalovirus retinitis</a></li></ul></div></div>","javascript":null}